Clinical trials: Angiogenesis
Colon Cancer, Lung Cancer
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
Background: Fluciclatide is a small cyclic peptide containing the RGD tri-peptide, which preferentially binds with high affinity to alpha(v)beta(3) integrins, which are up-regulated in and may regulate angiogenesis.
- Conditions
- Colon Cancer, Lung Cancer, Cervical Cancer, Renal Cell Carcinoma
- Trial name
- NCT01176500
- Testing
- (18)Fluciclatide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Neoadjuvant Itraconazole in Non-small Cell Lung Cancer
The purpose of this study is to determine the pharmacodynamics effects of itraconazole in early-stage non-small cell lung cancer.
- Trial name
- NCT02357836
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center
Colorectal Neoplasms
Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
The purpose of this study is to determine whether Endostar pumping into vein with Thalidomide are more effective in the treatment of Advanced Colorectal Cancer (ACRC).
- Trial name
- NCT02748772
- Testing
- Two Anti-angiogenesis Drugs（Endostar and Thalidomide）, Pure chemotherapy（Xelox）
- Where
- 3 sites in China
- Volunteers
- 148 people
- Sponsor
- The First People's Hospital of Hefei
Glaucoma
Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma
Refractory glaucoma often requires vision-sparing trabeculectomy. To increase surgical success, adjunctive pharmacotherapy is utilized albeit the risk of adverse events.
- Trial name
- AvastinvsMMC (NCT02901236)
- Testing
- Standard Guarded Trabeculectomy, Mitomycin C, Bevacizumab
- Volunteers
- 40 people
- Sponsor
- Athens Vision Eye Institute
Glioblastoma
Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma
Despite an aggressive therapeutic approach, the prognosis for most patients with glioblastoma (GBM) remains poor. The relationship between non-invasive Magnetic Resonance Imaging (MRI) biomarkers at preoperative, postradiotherapy…
- Trial name
- ONCOhabitats (NCT03439332)
- Where
- Spain
- Volunteers
- 305 people
- Sponsor
- Juan M Garcia-Gomez
Peripheral Vascular Disease, Diabetic Foot
Autologous Bone Marrow Stem Cell Transplantation for Critical, Limb-threatening Ischemia
Critical limb ischemia is a condition where the blood circulation in the limbs, in most cases the legs, is decreased so that pain and non healing wounds ensue. Mostly, this is a sequel of arteriosclerosis and/or diabetes.
- Conditions
- Peripheral Vascular Disease, Diabetic Foot, Peripheral Arterial Occlusive Disease, Leg Ulcer
- Trial name
- BONMOT (NCT00434616)
- Testing
- Autologous bone marrow cell concentrate transplantation, saline injection
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Franziskus-Krankenhaus
Colorectal Cancer Metastatic
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced…
- Trial name
- NCT06682247
- Testing
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
- Volunteers
- 200 people
- Sponsor
- Feng Wang
Glioblastoma
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Angiopoietin-2 (Ang-2) is a protein in the body which destabilizes blood vessels and is important in stimulating tumor blood vessels.
- Trial name
- NCT01225510
- Testing
- PF-04856884
- Sponsor
- Pfizer
Lung Neoplasms, Carcinoma, Non-small Cell Lung
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e.…
- Trial name
- NCT00094094
- Testing
- axitinib
- Where
- 11 sites in United States, Germany
- Volunteers
- 32 people
- Sponsor
- Pfizer
Glioblastoma, Angiogenesis
Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab.
- Trial name
- NCT04974983
- Testing
- Observation of neurological deficits
- Where
- Germany
- Volunteers
- 203 people
- Sponsor
- University Hospital Regensburg
Prostatic Neoplasms
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Background: Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate tumors respond to it.
- Trial name
- NCT01683994
- Testing
- Cabozantinib, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Myelofibrosis
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic…
- Trial name
- NCT00667277
- Testing
- bevacizumab (Avastin)
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Ronald Hoffman
Renal Cell Carcinoma
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004).
- Trial name
- NCT01206764
- Testing
- RAD001
- Where
- 22 sites in Algeria, Egypt and 8 more
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
Corneal Graft Rejection, CD160
CD160 Expression in Corneal Vessels
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to…
- Conditions
- Corneal Graft Rejection, CD160, Angiogenesis, Lymphangiogenesis
- Trial name
- NCT05009407
- Testing
- Immunohistochemistry and clinical analyses on patients and corneas
- Where
- France
- Volunteers
- 43 people
- Sponsor
- CHU de Reims
Prostate Cancer
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
The goal of this clinical research study is to learn the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer.
- Trial name
- NCT00631527
- Testing
- Leuprolide, Goserelin, Sunitinib Malate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma, Soft Tissue Sarcoma
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Locally Advanced Sarcoma, Unresectable Sarcoma
- Trial name
- NCT01106872
- Testing
- Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Mohammed M Milhem
Pregnancy, Pre Eclampsia
Pre-Eclampsia Prediction By Doppler Screening Of Uterine Arteries And Angiogenic Factors In Second Trimester Of Pregnancy
BACKGROUND: Pre-eclampsia complicates about 2% of pregnancies. It accounts for at least 50 000 maternal deaths per year worldwide and is the second most common cause of maternal death in the developing world.
- Trial name
- NCT00725660
- Where
- Israel
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Inflammatory Breast Carcinoma
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
This research study is a pilot study, which tests the ability of an investigational compound to be used in humans for further studies. "Investigational" means that 89Zr-bevacizumab for PET/CT imaging is being studied.
- Trial name
- NCT01894451
- Testing
- 89Zr-bevacizumab, FDG-PET/CT, MRI scan
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Sarcoma, Alveolar Soft Part
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS.
- Trial name
- NCT01391962
- Testing
- Cediranib, Sunitinib, Prochlorperazine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Pre-Eclampsia
Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia.
Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries.
- Trial name
- NCT06122220
- Testing
- ONSD+AF
- Where
- Panama
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Saint Thomas Hospital, Panama